{"id":"NCT01422876","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients","officialTitle":"A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Individual Components (BI 10773 25 mg, BI 10773 10 mg, and Linagliptin 5 mg) for 52 Weeks in Treatment naïve and Metformin Treated Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2011-08-25","resultsPosted":"2015-04-02","lastUpdate":"2015-04-02"},"enrollment":1405,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"high dose FDC","otherNames":[]},{"type":"DRUG","name":"BI 10773 high dose","otherNames":[]},{"type":"DRUG","name":"high dose FDC placebo","otherNames":[]},{"type":"DRUG","name":"low dose FDC placebo","otherNames":[]},{"type":"DRUG","name":"high dose FDC placebo","otherNames":[]},{"type":"DRUG","name":"high dose FDC placebo","otherNames":[]},{"type":"DRUG","name":"low dose FDC placebo","otherNames":[]},{"type":"DRUG","name":"low dose FDC placebo","otherNames":[]},{"type":"DRUG","name":"high dose BI 10773 placebo","otherNames":[]},{"type":"DRUG","name":"low dose FDC","otherNames":[]},{"type":"DRUG","name":"high dose FDC placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773 low dose","otherNames":[]},{"type":"DRUG","name":"high dose BI 10773 placebo","otherNames":[]},{"type":"DRUG","name":"high dose BI 10773 placebo","otherNames":[]},{"type":"DRUG","name":"linagliptin","otherNames":[]},{"type":"DRUG","name":"low dose FDC placebo","otherNames":[]},{"type":"DRUG","name":"linagliptin placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773 low dose placebo","otherNames":[]},{"type":"DRUG","name":"linagliptin placebo","otherNames":[]},{"type":"DRUG","name":"low dose BI 10773 placebo","otherNames":[]},{"type":"DRUG","name":"linagliptin placebo","otherNames":[]},{"type":"DRUG","name":"high dose BI 10773 placebo","otherNames":[]},{"type":"DRUG","name":"BI 10773 low dose placebo","otherNames":[]},{"type":"DRUG","name":"low dose BI 10773 placebo","otherNames":[]},{"type":"DRUG","name":"linagliptin placebo","otherNames":[]}],"arms":[{"label":"BI 10773/linagliptin FDC (high dose)","type":"EXPERIMENTAL"},{"label":"BI 10773/linagliptin FDC (low dose)","type":"EXPERIMENTAL"},{"label":"BI 10773 (high dose)","type":"ACTIVE_COMPARATOR"},{"label":"BI 10773 (low dose)","type":"ACTIVE_COMPARATOR"},{"label":"Linagliptin","type":"ACTIVE_COMPARATOR"}],"summary":"This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg","deltaMin":-1.19,"sd":0.06},{"arm":"Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg","deltaMin":-1.08,"sd":0.06},{"arm":"Metformin Background: Empagliflozin 25 mg","deltaMin":-0.62,"sd":0.06},{"arm":"Metformin Background: Empagliflozin 10 mg","deltaMin":-0.66,"sd":0.06},{"arm":"Metformin Background: Linagliptin 5 mg","deltaMin":-0.7,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG004","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":211,"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Canada","Colombia","Denmark","Estonia","Hungary","Italy","Lebanon","Malaysia","Mexico","Peru","Philippines","Poland","Romania","Russia","Spain","Sweden","Taiwan"]},"refs":{"pmids":["29949041","25633662","25583754"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":273},"commonTop":["Urinary tract infection","Headache","Upper respiratory tract infection","Nasopharyngitis","Hyperglycaemia"]}}